Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4787611
Max Phase: Preclinical
Molecular Formula: C75H114N20O20
Molecular Weight: 1615.86
Molecule Type: Unknown
Associated Items:
ID: ALA4787611
Max Phase: Preclinical
Molecular Formula: C75H114N20O20
Molecular Weight: 1615.86
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CC(C)C)C(=O)O
Standard InChI: InChI=1S/C75H114N20O20/c1-8-40(6)60(70(111)92-54(73(114)115)34-39(4)5)93-67(108)52(36-43-19-23-45(97)24-20-43)91-69(110)56-16-12-32-95(56)72(113)49(14-10-30-82-75(79)80)87-61(102)46(13-9-29-81-74(77)78)86-68(109)55-15-11-31-94(55)71(112)41(7)83-64(105)53(37-57(76)98)90-63(104)48(26-28-59(100)101)85-66(107)51(35-42-17-21-44(96)22-18-42)89-65(106)50(33-38(2)3)88-62(103)47-25-27-58(99)84-47/h17-24,38-41,46-56,60,96-97H,8-16,25-37H2,1-7H3,(H2,76,98)(H,83,105)(H,84,99)(H,85,107)(H,86,109)(H,87,102)(H,88,103)(H,89,106)(H,90,104)(H,91,110)(H,92,111)(H,93,108)(H,100,101)(H,114,115)(H4,77,78,81)(H4,79,80,82)/t40-,41-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,60-/m0/s1
Standard InChI Key: OTLPIQWBPFSTMH-KCODUONZSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1615.86 | Molecular Weight (Monoisotopic): 1614.8518 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Chartier M,Desgagné M,Sousbie M,Côté J,Longpré JM,Marsault E,Sarret P. (2021) Design, Structural Optimization, and Characterization of the First Selective Macrocyclic Neurotensin Receptor Type 2 Non-opioid Analgesic., 64 (4.0): [PMID:33538583] [10.1021/acs.jmedchem.0c01726] |
Source(1):